Memphis Pharmaceuticals results, Q2 2022
Net profit, assets, equity and cash flow for Q2 2022, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit14 millionEGP
Total assets434 millionEGP
Shareholders' equity-29.54 millionEGP
Operating cash flow-5.25 millionEGP
In short
- Memphis Pharmaceuticals's net profit for Q2 2022 was about 14 million EGP.
- Total assets at the end of Q2 2022 were about 434 million EGP, and shareholders' equity about -29.54 million EGP.
- Operating cash flow for Q2 2022 was negative at 5.25 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit14 million——
Gross profit49.4 million——
Total assets434 million——
Total liabilities463 million——
Shareholders' equity-29.54 million——
Total liabilities and equity434 million——
Operating cash flow-5.25 million——
Investing cash flow-1.4 million——
Financing cash flow———
Net change in cash-6.65 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Memphis Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy